Company: RPTX
Filing Date: 2025-12-03
Form Type: PREM14A
Source: 0001193125-25-306948
Chunk: 62

Company: Repare Therapeutics Inc.
Filing Date: 2025-12-03
Form: PREM14A
Chunk 62
---
 Blue Owl Healthcare Opportunities, and certain entities affiliated with OrbiMed to obtain their feedback on the proposed Arrangement and to gauge their interest

34

in supporting the Arrangement at the Meeting. Following negotiations with such shareholders on the terms of the support and voting agreements, on November 20, 2025, the Company and such shareholders entered into the Voting and Support Agreements. As of the date hereof, Company management continues to engage with Party A for the potential disposition of RP-3467. Recommendation of the Transaction Committee The Transaction Committee, with the advice and assistance of its independent legal and financial advisors, evaluated the Arrangement and the terms and conditions of the Agreement. At a meeting held on November 14, 2025, the Transaction Committee unanimously determined that the Consideration to be received by the Shareholders pursuant to the Arrangement is fair to the Shareholders and that the Arrangement is in the best interests of the Company. The Transaction Committee unanimously recommended that the Board (i) approve the Agreement; and (ii) recommend that the Shareholders vote “FOR” the Arrangement Resolution. Reasons for the Arrangement In evaluating the Arrangement, the Agreement, and the other transactions and agreements contemplated thereby, the Transaction Committee and the Board consulted with legal and financial advisors, consulted with the Company’s management and considered a number of factors, including, but not limited to, the following material factors (not necessarily in order of relative importance):

| • |     | Certainty of Value — The (i) cash amount to be received by Shareholders provides                                                                                                                                                                    
 certain and immediate value and liquidity to the Shareholders for their Common Shares and (ii) CVR may provide additional value and liquidity to the Shareholders for their Common Shares, especially when viewed against the internal and external 
 risks and uncertainties associated with macroeconomic conditions, including the current state of the U.S. and global economies, and the potential impact of such risks, the trading price of the Common Shares on Nasdaq and the potential for an   
 alternative strategic transaction.                                                                                                                                                                                                                  |

| • |     | Accelerating and Maximizing Cash Payment — In furtherance of the Discontinuance, the                                                                                                                                                                   
 Arrangement is expected to maximize the amount of cash that will be paid to Shareholders and to provide Shareholders with cash sooner than would be the case in the context of a statutory liquidation which has been determined to be the only other  
 viable alternative transaction available to the Company. Further, the cash amount to be received